Posted by Michael Wonder on 31 Jul 2019
Ezetimibe reduces the risk of heart attacks and strokes
26 July 2019 - Added to existing statin therapy, ezetimibe is preventative in patients with CHD and acute coronary syndrome.
In patients with a history of coronary heart disease or a history of acute coronary syndrome, it is more beneficial to be treated with a statin in combination with ezetimibe than with a statin alone. On the other hand, there is no hint that the combination therapy statin plus ezetimibe is also superior to the combination of a statin with the lipid-lowering agent alirocumab. No studies were available for other lipid-lowering combination partners.
These are the findings of the Institute for Quality and Efficiency in Health Care (IQWiG) in a current benefit assessment commissioned by the Federal Joint Committee (G-BA) in November 2018.
